---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: pfm0@cdc.gov, pmead@cdc.gov
Cc: tickbornedisease@hhs.gov (97 Undisclosed recipients)
Date: September 18, 2019 at 9:58 AM
Subject: Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease
Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease
Weekly / August 16, 2019 / 68(32);703
https://www.cdc.gov/mmwr/volumes/68/wr/mm6832a4.htm
Paul Mead, MD; Jeannine Petersen, PhD; Alison Hinckley, PhD
On July 29, 2019, the Food and Drug Administration (FDA) cleared several Lyme disease serologic assays with new indications for use, allowing for an EIA rather than western immunoblot assay as the second test in a Lyme disease testing algorithm.
Corresponding author: Paul Mead, pmead@cdc.gov, 970-221-6474
Sept 18, 2019
Division of Vector-Borne Diseases
Centers for Disease Control and Prevention
3156 Rampart Rd
Fort Collins, Colorado CO 80521
Attn: Paul Mead, MD, MPH Acting Branch Chief pfm0@cdc.gov
Dr. Mead,
You were a coauthor of the Schutzer paper published last October calling for direct diagnostic tests for Lyme disease:
Direct Diagnostic Tests for Lyme Disease
https://doi.org/10.1093/cid/ciy614
Excerpt:
“… serologic tests cannot distinguish active infection, past infection, or reinfection. Reliable direct-detection methods for active B. burgdorferi infection have been lacking in the past but are needed and appear achievable.”
Based on the recent CDC Recommendation for Serologic Diagnosis, it would appear that the statement above is little more than lip service.
It appears that the new ZEUS MTTT test that you are promoting is a creation from the attached Raymond J. Dattwyler patent filed in 2011.
https://www.dropbox.com/s/3fbv4q8tryhmk4t/Raymond%20J.%20Dattwyler%20Patent%20IR6_pepC10.pdf?dl=0
Excerpt:
Furthermore, a diagnostic test of the invention (e.g. an ELISA assay) is useful in serum samples that contain anti-OspA antibodies or other antibodies produced in response to a vaccine based on the outer Surface proteins of Borrelia; a VlsB IR6 peptide of the invention does not cross-react with such antibodies, thereby allowing the differentiation of vaccinated individuals from individuals who were naturally infected with B. burgdorferi.
_____________________
So it would appear that it’s all about the Vaccine.
In fact, the mishandling of Lyme disease here in the United States has always been about the vaccine, hasn’t it Dr. Mead?
From the proceedings of the Second National Conference on Serologic Diagnosis of Lyme Disease; October 27–29, 1994 in Dearborn where Bands 31 (OspA) and 34 (OspB) were stripped out of the Western blot to insure the vaccinated would test seronegative.
A chronic relapsing seronegative disease doesn’t fit the vaccine model.
Everything that has been put in place was done so to hide a horribly disabling disease that destroys the immune system misclassifying this disease as a low-risk and non-urgent health risk while focusing on the acute stage of disease (with bulls-eye rash) after early treatment hiding/avoiding the horribly disabled who went months, years or decades untreated.
The vaccine was supposed to be a cure-all for an incurable disease.
All evidence points to those who were involved in the vaccine debacle (defendants of the racketeering lawsuit) that have a cozy relationship with the US Centers for Disease Control.
The vaccine by the way caused the same debilitating effects as the disease itself as identified in the class action lawsuit below. For the record, LYMErix was not withdrawn from the market due to slow sales.
Judgement, Final Order and Decree Granting Final Approval of the Class Action Settlement
https://www.dropbox.com/s/v3gyw4fv8nst9bz/2003_Vaccine_Judgement_Final_Sttle_Apprvl..pdf?dl=0
To my knowledge there was no follow-up research to determine why this class of patient suffered the reaction they experienced. Is there a genetic predisposition that could give a similar reaction to the next OspA vaccine currently on Fast Track with the FDA? This is like playing Russian roulette with public health.
Newsweek
LYME DISEASE VACCINE ON FAST TRACK FOR FDA APPROVAL
https://www.newsweek.com/lyme-disease-vaccine-valneva-fda-approva-641796
____________________
As for “Direct Diagnostic Tests for Lyme Disease” what is the status of NIST which I understand has been put on the shelf?
New Experimental Test Detects Signs of Lyme Disease Near Time of Infection
February 11, 2016
And what about DNA/Sanger Sequencing? After Dr. Sin Lee published a case of chronic Lyme disease identified in blind coded serum samples supplied by the CDC your agency abruptly stopped communicating before attempting proficiency testing of his technology. 16S ribosomal RNA gene sequencing is a reliable molecular diagnostic tool in diagnosis of bacterial infections.
UNITED STATES COURT OF FEDERAL CLAIMS Case No. 18-686C
COMPLAINT:
https://www.dropbox.com/s/zem4v9sceg1v63d/Lee%20CDC%20Complaint%205-15-2018.pdf?dl=0
From the CDC website:
Why is CDC concerned about Lyme disease?
https://www.cdc.gov/lyme/why-is-cdc-concerned-about-lyme-disease.html
Improving Early and Accurate Diagnosis
CDC scientists, in collaboration with researchers from Colorado State University are working to develop a new type of test to help healthcare providers diagnose early Lyme disease using an innovative approach called “metabolomics.”
______________________
It appears that employees of the U.S. Centers for Disease Control hold patents on “metabolomics”.
CDC Employee Patent: https://www.google.com/patents/EP2805168A1?cl=en
Inventor: Theresa M. RUSSELL, Barbara J.B. JOHNSON
So what’s really going on here Dr. Mead? Is avoidance of Direct Detection Methods for the purpose of concealing persistent infection (chronic Lyme) fraud/scientific misconduct?
It looks like we can’t have direct detection methods because the truth would be exposed.
Please correct me if I have miscalculated anything described in this letter.
A response to this inquiry is requested.
Carl Tuttle
Lyme Endemic Hudson, NH